Benedikt Richter, a 40-year-old teacher in the southwest German city of Kaiserslautern, has long held out against getting vaccinated against Covid-19. He felt uneasy about the novelty of the mRNA technology used in two of the most commonly administered shots.

But when the European Union in December approved the use of the Novavax vaccine Nuxavoxid, which deploys a long-established protein-based technology, he became interested. "I have done my research and I have a slightly better feeling about it," said the father of two.

Data unearthed by Reuters suggests the new two-dose vaccine, recommended in Germany for basic immunisation for people over 18, is already going some way to convince more of the as-yet unvaccinated to get a shot.

Read the full story here.